Purpose
To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).
Materials and Methods
We conducted a retrospective review of 64 consecutive patients with UM treated with Cyberknife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range 48-64 Gy) administered in four fractions every alternate day. The local failure-free rate (LFFR), distant metastasis-free rate (DMFR), progression-free survival (PFS), and overall survival (OS) were assessed using the Kaplan–Meier method and log-rank test. Cox regression analysis was performed to analyze the predictive factors affecting survival outcomes and the factors associated with vision loss.
Results
The median tumor diameter and height were 11.5 mm and 8.4 mm, respectively. After a median follow-up of 32.1 months (range 4.9–89.9), the 3-year LFFR, DMFR, PFS, and OS were 89.5%, 70.5%, 65.5%, and 89.4%, respectively. Enucleation was performed in 13 (20.3%) patients, with three cases attributed to disease progression. A larger tumor diameter was associated with significantly worse DMFR (HR=1.35, p=0.015) and OS (HR=1.49, p=0.026) in the multivariate analysis. Regarding visual prognosis, 41 (64.1%) patients had baseline visual acuity ≥20/200, but only 4 (6.3%) patients maintained visual acuity ≥20/200 by the final follow-up. Initial visual acuity ≥20/40 (HR 0.45, p=0.030) was the single favorable significant factor predicting visual retention ≥20/200 in multivariate analysis.
Conclusion
SBRT using CyberKnife demonstrated a comparable local control rate to that observed in historical studies for patients with large UM. Distant metastasis and treatment-related ocular toxicity remain the limitations of this treatment.
Boram Ha, Kwan Ho Cho, Sung Ho Moon, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Jong Hoon Lee, Sung Hwan Kim, Won Taek Kim, Young-Taek Oh, Min Kyu Kang, Jin Hee Kim, Ji-Yoon Kim, Moon-June Cho, Chul Seoung Kay, Jin Hwa Choi
Cancer Res Treat. 2019;51(1):12-23. Published online February 5, 2018
Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170).
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.
Citations
Citations to this article as recorded by
Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy Wenyan Yao, Jiang Hu, Peixun Xu, Mengxue He, Yongwen Fang, Mingzhi Liu, Zongtai Li, Huilang He, Hui Liu, Wenzhao Sun, Senkui Xu Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes Jerry Ye Aung Kyaw, Alice Rendall, Erin F. Gillespie, Tom Roques, Laurence Court, Yolande Lievens, Alison C. Tree, Chris Frampton, Ajay Aggarwal International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1063. CrossRef
The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature Stephanie Flukes, Rahul K. Sharma, Shivangi Lohia, Marc A. Cohen Journal of Neurological Surgery Part B: Skull Base.2022; 83(03): 270. CrossRef
A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma Khodayar Goshtasbi, Brandon M. Lehrich, Jack L. Birkenbeuel, Arash Abiri, Jeremy P. Harris, Edward C. Kuan Otolaryngology–Head and Neck Surgery.2021; 165(1): 93. CrossRef
Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy Tzu-Yu Lai, Chiu-Mei Yeh, Yu-Wen Hu, Chia-Jen Liu Radiotherapy and Oncology.2020; 151: 190. CrossRef
Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood ofrecurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression-free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy.
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)‒negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival.
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.
Citations
Citations to this article as recorded by
Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery Louis Cappelli, Mehak M. Khan, Carol L. Shields, Sara E. Lally, Muhammad Sharif, Haisong Liu, Yingxuan Chen, Jade Park, Tingting Zhan, Wenyin Shi American Journal of Ophthalmology.2025; 271: 417. CrossRef
Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives Merve Kulbay, Emily Marcotte, Raheem Remtulla, Tsz Hin Alexander Lau, Manuel Paez-Escamilla, Kevin Y. Wu, Miguel N. Burnier Biomedicines.2024; 12(8): 1758. CrossRef
Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard Cancers.2024; 16(19): 3346. CrossRef
Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma Binghua Yang, Yuxia Fan, Renlong Liang, Yi Wu, Aiping Gu BMC Ophthalmology.2023;[Epub] CrossRef
Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result Yaping Su, Xiaolin Xu, Fang Wang, Panli Zuo, Qinghua Chen, Wenbin Wei, Junfang Xian Journal of Computer Assisted Tomography.2023; 47(1): 151. CrossRef
Uveal melanoma pathobiology: Metastasis to the liver Prisca Bustamante, Léo Piquet, Solange Landreville, Julia V. Burnier Seminars in Cancer Biology.2021; 71: 65. CrossRef
Malignant uveal melanoma with metastatic recurrence to the pancreas: A case report Wei‐Chun Weng, Tzung‐Jiun Tsai, Wen‐Chi Chen, Jin‐Shiung Cheng, Wei‐Chih Sun Advances in Digestive Medicine.2021; 8(3): 178. CrossRef
Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort Paula Silva‐Rodríguez, Manuel Bande, Daniel Fernández‐Díaz, Nerea Lago‐Baameiro, María Pardo, María José Blanco‐Teijeiro, Fernando Domínguez, Lourdes Loidi, Antonio Piñeiro Acta Ophthalmologica.2021;[Epub] CrossRef
Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort Laura Ling Ying Tan, Jiancheng Hong, Wei Lin Goh, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Anita Sook Yee Chan, Jason Yongsheng Chan Scientific Reports.2020;[Epub] CrossRef
ЕФЕКТИВНІСТЬ РАДІОХВИЛЬОВОЇ (3,8 МГЦ) БЛОКЕКСЦИЗІЇ МЕЛАНОМИ ЦИЛІОХОРІОЇДАЛЬНОЇ ЛОКАЛІЗАЦІЇ O. V. Khomyakova Здобутки клінічної і експериментальної медицини.2020; (3): 173. CrossRef
Purpose
The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT).
Materials and Methods
Between January 2002 andDecember 2016, 102 patientswith stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomeswere compared between two groups. The expression of p16 was also analyzed.
Results
The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median followup of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021).
Conclusion
Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.
Citations
Citations to this article as recorded by
Treatment de‐escalation for HPV+ oropharyngeal cancer: A systematic review and meta‐analysis Fausto Petrelli, Andrea Luciani, Antonio Ghidini, Sara Cherri, Paolo Gamba, Marta Maddalo, Paolo Bossi, Alberto Zaniboni Head & Neck.2022; 44(5): 1255. CrossRef
Ginsenoside Rd inhibits migration and invasion of tongue cancer cells through H19/miR-675-5p/CDH1 axis Lu CHANG, Dongxu WANG, Shaoning KAN, Ming HAO, Huimin LIU, Zhijing YANG, Qianyun XIA, Weiwei LIU Journal of Applied Oral Science.2022;[Epub] CrossRef
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques Tae Hyung Kim, In-Ho Cha, Eun Chang Choi, Hye Ryun Kim, Hyung Jun Kim, Se-Heon Kim, Ki Chang Keum, Chang Geol Lee Frontiers in Oncology.2021;[Epub] CrossRef
Superficial circumflex iliac artery perforator flap for tongue reconstruction after hemiglossectomy for cancer: A case report Hong Loi Nguyen, Truong Phu M. Ho, Xuan Phu Tran, Thanh Xuan Nguyen Oral and Maxillofacial Surgery Cases.2021; 7(2): 100219. CrossRef
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy Ambika Parmar, Michaelina Macluskey, Niall Mc Goldrick, David I Conway, Anne-Marie Glenny, Janet E Clarkson, Helen V Worthington, Kelvin KW Chan Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Larynx-preserving reconstruction after extended base of the tongue resection Hideki Kadota, Junichi Fukushima, Sei Yoshida, Kenichi Kamizono, Muneyuki Masuda, Satoshi Toh, Ryuji Yasumatsu, Torahiko Nakashima, Takashi Nakagawa Journal of Plastic, Reconstructive & Aesthetic Surgery.2020; 73(4): 740. CrossRef
Purpose
The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru) brachytherapy with or without additional local therapy for choroidal melanomas in Korean patients.
Materials and Methods
A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru brachytherapy between 2006 and 2012. Patients were divided into two groups according to their tumor height: a large group (≥ 6 mm, n=50) and a small group (< 6 mm, n=38). Most patients in the large group received combined therapy with local excision and/or transpupillary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while 100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients undergoing combined therapy.
Results
The median follow-up duration was 30 months. The 3-year local control rate was significantly higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%; p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor height was a significant prognostic factor for eye-preservation.
Conclusion 106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean patients. Although additional local treatment could improve eye-preservation rate for large tumors, other strategies should be considered for disease control.
Citations
Citations to this article as recorded by
Incidence, risk factors and outcomes of cataract surgery after plaque brachytherapy for posterior uveal melanoma Viktor T. Gill, Gustav Stålhammar Heliyon.2024; 10(1): e23447. CrossRef
Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma Gustav Stålhammar International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1125. CrossRef
The Role of Ruthenium Compounds in Neurologic Diseases: A Minireview Fátima Virgínia Gama Justi, Gabriella Araújo Matos, Juan de Sá Roriz Caminha, Cássia Rodrigues Roque, Edinilton Muniz Carvalho, Márcio Wilker Soares Campelo, Ludmila Belayev, Luiz Gonzaga de França Lopes, Reinaldo Barreto Oriá The Journal of Pharmacology and Experimental Therapeutics.2022; 380(1): 47. CrossRef
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy Gilda Cennamo, Daniela Montorio, Luca D’ Andrea, Antonio Farella, Elide Matano, Mario Giuliano, Raffaele Liuzzi, Maria Angelica Breve, Sabino De Placido, Giovanni Cennamo Frontiers in Oncology.2022;[Epub] CrossRef
Uveal Melanoma: A Review of the Literature and Personal Experiences Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee Journal of Retina.2021; 6(2): 65. CrossRef
Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma Daniel Lorenzo, María Ochoa, Josep Maria Piulats, Cristina Gutiérrez, Luis Arias, Jaume Català, María Grau, Judith Peñafiel, Estefanía Cobos, Pere Garcia-Bru, Marcos Javier Rubio, Noel Padrón-Pérez, Bruno Dias, Joan Pera, Josep Maria Caminal Cancer Research and Treatment.2018; 50(4): 1130. CrossRef
Purpose
The purpose of this study was to compare the treatment outcomes of definitive radiotherapy (RT) with cordectomy in patients with early glottic cancer.
Materials and Methods
A total of 165 patientswhowere diagnosedwith T1/2 squamous cell carcinoma of the glottic larynx between January 2006 and December 2012 were retrospectively analyzed. A total of 112 patients received RT and 53 patients received cordectomy. Local control (LC), disease-free survival (DFS), overall survival (OS), and larynx preservation rates after RT and cordectomy were investigated.
Results
The median follow-up period was 77.7 months (range, 10.7 to 127.0 months). The 3- and 5-year LC rates were 91.9% and 89.9%, respectively, for the RT group, and 82.8% and 73.2%, respectively, for the cordectomy group (p=0.006). The 3- and 5-year DFS rates were 87.5% and 83.7%, respectively, for the RT group and 79.2% and 68.0%, respectively, for the cordectomy group (p=0.046). No significant differences were identified in the 5-year OS (92.8% vs. 90.6%, p=0.713) or larynx preservation rates (98.2% vs. 97.2%, p=0.831) between groups. The major failure pattern was local failure (n=26), followed by regional (n=3) and distant failure (n=2). Multivariate analysis of LC showed that T2 stage (p=0.012) and receiving cordectomy as initial treatment (p=0.001) were significantly associated with poorer LC.
Conclusion
RT resulted in higher rates of LC and DFS compared to cordectomy for early glottic cancer. Treatment with radiotherapy is feasible and should be encouraged for both T1 and T2 glottic cancer.
Citations
Citations to this article as recorded by
Particular aspects of laser microsurgery in malignant and premalignant glottic lesions Mihai Tușaliu, Costinel Adrian Vrejoiu, Iulia Tiţă, Mădălina Vulpe, Adriana Lozbă, Cristian Bucur ORL.ro.2024; 1(62): 9. CrossRef
Oncological outcomes of surgical management for T2N0M0 glottic laryngeal squamous cell carcinoma Jian Zhou, Cheng‐Zhi Xu, Xiao‐Ke Zhu, Yue Yang, Liang Zhou, Hong‐Li Gong, Lei Tao World Journal of Otorhinolaryngology - Head and Neck Surgery.2024;[Epub] CrossRef
The association between initiation weekday of radiotherapy and local control in stage 1 glottic carcinoma: a retrospective analysis Masashi Endo, Satoru Takahashi, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Michiko Nakamura, Masahiro Kawahara, Keiko Akahane, Eri Murakami, Chiaki Shibayama, Ryutaro Onaga, Takafumi Nagatomo, Takeharu Kanazawa, Hiroshi Nishino, Harushi Mori, Katsuyuki S Journal of Radiation Research.2024; 65(6): 798. CrossRef
The Same–Up–Down Staging System for Recurrent Early Glottic Cancer Giuseppe Licci, Luca Giovanni Locatello, Giandomenico Maggiore, Flavia Cozzolino, Saverio Caini, Oreste Gallo Cancers.2023; 15(3): 598. CrossRef
Kehlkopfteilresektion – eine interdisziplinäre Gratwanderung zwischen Resektion und Funktionserhalt Manuel Christoph Ketterer, Rainer Beck, Matthias Cohnen, Andreas Knopf best practice onkologie.2023; 18(5): 184. CrossRef
Intensity-Modulated Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx: A Systematic Review and Meta-Analysis Niema B. Razavian, Ralph B. D'Agostino, Rachel F. Shenker, Ryan T. Hughes International Journal of Radiation Oncology*Biology*Physics.2023; 117(3): 652. CrossRef
Clinical Analysis of the Treatment Outcomes of Laryngeal Cancer Takashi Kurita, Shun-ichi Chitose, Takeharu Ono, Mioko Fukahori, Shintaro Sueyoshi, Ryota Mihashi, Toshihiko Kawaguchi, Akira Hiraki, Hirohito Umeno Practica oto-rhino-laryngologica. Suppl..2023; 163: 89. CrossRef
Comparison of Survival Outcomes of Different Treatment Options for cT1-2, N0 Glottic Carcinoma: A Propensity Score–Weighted Analysis Qi-wei Liang, Liang Peng, Jing Liao, Chun-xia Huang, Wei-ping Wen, Wei Sun Frontiers in Surgery.2022;[Epub] CrossRef
Survival study in early stages of glottis cancer, stratified by treatment Yolanda Lois-Ortega, Fernando García-Curdi, Héctor Vallés-Varela, Ana Muniesa-del Campo Acta Oto-Laryngologica.2022; 142(7-8): 627. CrossRef
Selective local postoperative radiotherapy for T3–T4 N0 laryngeal cancer Meltem Dağdelen, Merve Şahin, Tuba Kurt Çatal, Halil Cumhur Yıldırım, Songül Çavdar Karaçam, Kimia Çepni, Ömer Erol Uzel Strahlentherapie und Onkologie.2022; 198(11): 1025. CrossRef
Long-term impact of smoking cessation on new glottic cancer events in patients with early glottic cancer Min-Su Kim, Hong-Gyun Wu, Myung-Whun Sung, Tack-Kyun Kwon Acta Otorhinolaryngologica Italica.2022; 42(6): 525. CrossRef
Diode Laser for Laryngeal Cancer: “980 nm” and Beyond the Classic CO2 Petros D. Karkos, Ioannis Koskinas, Marios Stavrakas, Stefanos Triaridis, Jannis Constantinidis Ear, Nose & Throat Journal.2021; 100(1_suppl): 19S. CrossRef
Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients Ruichen Li, Qi Wang, Li Yan, Yi Zhu, Shengzi Wang, Shu Tian Oral Oncology.2021; 116: 105230. CrossRef
Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients Gerhard Dyckhoff, Rolf Warta, Christel Herold-Mende, Elisabeth Rudolph, Peter K. Plinkert, Heribert Ramroth Cancers.2021; 13(7): 1601. CrossRef
Age as Indicator in the Selection of Surgery Modalities in Early Glottic Cancer Jialing Wu, Kaiyun You, Xingsheng Qiu, Ting Shen, Juanjuan Song, Changlong Chen, Yanhui Jiang, Yimin Liu Risk Management and Healthcare Policy.2021; Volume 14: 3223. CrossRef
Feasibility of single vocal cord irradiation as a treatment strategy for T1a glottic cancer Seung Yeun Chung, Chang Geol Lee Head & Neck.2020; 42(5): 854. CrossRef
Radiotherapy versus laser microsurgery in the treatment of early glottic cancer Yolanda Lois-Ortega, Fernando García-Curdi, José Miguel Sebastián-Cortés, Félix De Miguel-García, Héctor Vallés-Varela, Ana Muniesa-del Campo Acta Oto-Laryngologica.2020; 140(11): 954. CrossRef
Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms Yajing Du, Shali Shao, Minghe Lv, Yi Zhu, Li Yan, Tiankui Qiao Frontiers in Oncology.2020;[Epub] CrossRef
Comparison between radiotherapy and transoral laser microsurgery treatments in early-stages of glottis cancer: A five-year follow-up study Javier Santabárbara Investigación Clínica.2020; 61(4): 324. CrossRef
Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma Simon Beyaert, Marc Hamoir, Aline Van Maanen, Vincent Grégoire, Sandra Schmitz European Journal of Surgical Oncology.2019; 45(7): 1188. CrossRef
Prognostic factors in patients with T1 glottic cancer treated with radiotherapy A. Mucha-Małecka, A. Chrostowska, K. Urbanek, K. Małecki Strahlentherapie und Onkologie.2019; 195(9): 792. CrossRef
Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature Martine Hendriksma, Elisabeth V. Sjögren Cancers.2019; 11(9): 1234. CrossRef
Treatment of early-stage laryngeal cancer: A comparison of treatment options Brandon Jackson Baird, C. Kwang Sung, Beth M. Beadle, Vasu Divi Oral Oncology.2018; 87: 8. CrossRef
Purpose
Although Korea has the highest incidence of gastric cancer worldwide and D2-lymphadenectomies are routinely performed, radiotherapy (RT) practice patterns have not been well studied. Therefore, we examined RT usage trends for neoadjuvant/adjuvant patients and identified factors associated with RT. We also examined survival benefits and net medical cost advantages of adding RT.
Materials and Methods
Patients diagnosed with gastric cancer who underwent gastrectomy from 2002-2013 were identified using National Health Insurance Service-National Sample Cohort.
Results
Annually, 30.9 cases per 100,000 population in crude rate underwent gastrectomy in 230 hospitals and 49.8% received neoadjuvant/adjuvant therapy in 182 hospitals. For neoadjuvant/adjuvant patients, postoperative chemo-RT was administered in 4% of cases in 26 hospitals. No significant trends regarding treatment type were observed over time. Having undergone RT was inversely associated with being ≥ 60 years old and having a low income. Having undergone RT was positively related to having a Charlson comorbidity index ≥ 4, hospital location and hospital volume (≥ 2,000 beds). Significant portions of patients treated with RT in this nation (52%) were concentrated in one large-volume hospital. Use of RT linked to increased cost of primary treatment, yet not to reduced overall medical expense. RT did not influence both on overall and disease-specific survivals after adjusting for potential confounders (p > 0.05).
Conclusion
RT was uncommonly utilized as adjuvant or neoadjuvant treatment by physicians in Korea. Despite intrinsic drawback in this data, we did not find either survival benefit or net medical cost advantage by adding RT in adjuvant treatment.
Citations
Citations to this article as recorded by
Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer Yung-Sung Yeh, Ming-Yii Huang, Cheng-Jen Ma, Ching-Wen Huang, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Fang-Jung Yu, Hsiang-Yao Shih, Jaw-Yuan Wang Journal of Oncology.2020; 2020: 1. CrossRef
Opportunities and limitations of CT - assessment of neoadjuvant chemoradiation therapy of gastric cancer T. A. Agababyan, N. K. Silanteva, V. Yu. Skoropad, S. A. Ivanov, A. D. Kaprin, Yu. A. Komin, A. Yu. Usacheva, D. D. Kudryavtsev Research and Practical Medicine Journal.2019; 6(4): 92. CrossRef
Outcomes of radiation therapy for resectable M0 gastric cancer Weipeng Gong, Hongwei Zhao, Shanshan Liu, Jie Guan, Xin Liu, Qingsheng Hou, Zhenyu Zhu, Hongliang Guo Oncotarget.2018; 9(2): 1726. CrossRef
Youngkyong Kim, Kwan Ho Cho, Sung Ho Moon, Chang Geol Lee, Ki Chang Keum, Sang-wook Lee, Yong Chan Ahn, Dongryul Oh, Yeon-Sil Kim, Yong Kyun Won, Hong-Gyun Wu, J. Hun Hah, Young-Taek Oh
Cancer Res Treat. 2017;49(4):1097-1105. Published online February 9, 2017
Purpose
The impact of postoperative ipsilateral neck radiotherapy (INRT) versus bilateral neck radiotherapy (BNRT) on the clinical outcomes of patients with tonsillar squamous cell carcinoma was analyzed retrospectively.
Materials and Methods
Between October 2001 and June 2012, 241 patients with T1-2 and N0-N2b tonsillar carcinoma from 16 institutes underwent postoperative INRT (n=84) or BNRT (n=157) following a tonsillectomy. Seventy patientswere identified from each group by propensity score matching and compared in terms of the overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates calculated using the Kaplan-Meier method with a log-rank test.
Results
The median follow-up was 55 months (range, 3 to 133 months). The survival outcomes in the INRT and BNRT groupswere similar: 5-year OS (92.8% vs. 94.0%, p=0.985), DFS (80.5% vs. 94.2%. p=0.085), LRRFS (88.1% vs. 97.1%, p=0.083), and DMFS (92.7% vs. 97.0%, p=0.370). Subgroup analysis revealed no contralateral neck recurrence in 61 patients with T1-2N0-2a regardless of the treatment groups. For 79 patients with N2b, contralateral neck recurrence was more common in the INRT group than in the BNRT group (7.9% vs. 0.0%), but the difference was not significant (p=0.107). The overall grade ≥ 2 toxicities were lower in the INRT group: acute (45.7% vs. 74.3%, p=0.001) and late (4.3% vs. 31.4%, p < 0.001), respectively.
Conclusion
INRT is an attractive strategy for patients with T1-2N0-2a tonsillar carcinoma compared to BNRT. For patients with N2b, there was a small risk of contralateral neck recurrence when treated with INRT, but its impact on the OS was limited with successful salvage treatment.
Citations
Citations to this article as recorded by
A multi‐institutional feasibility lead‐in trial of lymphatic mapping with SPECT–CT for evaluating contralateral disease in lateralized oropharynx cancer using 99m‐technetium sulfur colloid Leba Michael Sarkis, Christopher MKL Yao, Aaron Hendler, Ravi Mohan, Michael Au, Han Zhang, Antoine Eskander, Kevin Higgins, Danielle MacNeil, Sharon Tzelnick, David Goldstein, Ali Hosni, John R. de Almeida Head & Neck.2024; 46(12): 3038. CrossRef
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline Danielle N. Margalit, Christopher J. Anker, Michalis Aristophanous, Musaddiq Awan, Gopal K. Bajaj, Lisa Bradfield, Joseph Califano, Jimmy J. Caudell, Christina H. Chapman, Adam S. Garden, Paul M. Harari, Amanda Helms, Alexander Lin, Ellie Maghami, Ranee M Practical Radiation Oncology.2024; 14(5): 398. CrossRef
Proton pencil beam scanning radiotherapy in the postoperative treatment of p16 positive squamous cell tonsillar cancer – evaluation of toxicity and effectivity Jiří Kubeš, Sarah Al-Hamami, Silvia Sláviková, Pavel Vítek, Alexandra Haas, Kateřina Dědečková, Barbora Ondrová, Michal Andrlik, Matěj Navrátil, Eliška Rotnáglová, Vladimír Vondráček European Archives of Oto-Rhino-Laryngology.2024; 281(10): 5447. CrossRef
Unilateral radiotherapy for tonsillar cancer with multiple ipsilateral neck lymph nodes Tae Hyun Kim, Hong-Gyun Wu, Soon-Hyun Ahn, Woo-Jin Jeong, Wonjae Cha, Keun-Yong Eom Radiation Oncology Journal.2024; 42(3): 192. CrossRef
Impact of Postoperative Neck Radiotherapy Volumes on Long‐Term Unstimulated Saliva Flow Following Primary Surgery and Ipsilateral Neck Dissection for Oral Cavity Squamous Cell Carcinoma Claire M. Rooney, Shao Hui Huang, Jie Su, Scott Bratman, John Cho, John de Almeida, Michael Glogauer, David Goldstein, Ezra Hahn, Ali Hosni, Andrew Hope, Jonathan Irish, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, Jillian Tsai, John Waldron Head & Neck.2024;[Epub] CrossRef
Association of Unilateral Radiotherapy With Contralateral Lymph Node Failure Among Patients With Squamous Cell Carcinoma of the Tonsil Niema B. Razavian, Ralph B. D’Agostino, Cole R. Steber, Corbin A. Helis, Ryan T. Hughes JAMA Network Open.2023; 6(2): e2255209. CrossRef
Low contralateral neck recurrence risk with ipsilateral neck radiotherapy in N2b tonsillar squamous cell carcinoma Divya Natesan, Christina K. Cramer, Taofik Oyekunle, Donna Niedzwiecki, David M. Brizel, Yvonne M. Mowery Oral Oncology.2023; 139: 106362. CrossRef
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits Jared H Hara, Stanley I Gutiontov, Sophia Uddin, Ari J Rosenberg, Alexander T Pearson, Zhen Gooi, Elizabeth A Blair, Nishant Agrawal, Everett E Vokes, Daniel T Ginat, Daniel J Haraf, Aditya Juloori Cureus.2022;[Epub] CrossRef
Evaluating contralateral neck failure in patients with lateralized OPSCC treated with transoral robotic surgery and neck management based on pre-operative SPECT-CT lymphatic mapping Ilyes Berania, Ali Hosni, Carissa M. Thomas, David Goldstein, Andrew Bayley, Ravi Mohan, Aaron Hendler, Richard M. Cooper, John R. de Almeida Journal of Otolaryngology - Head & Neck Surgery.2022;[Epub] CrossRef
Short‐term and long‐term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma Shao Hui Huang, John R. de Almeida, Erin Watson, Michael Glogauer, Wei Xu, Sareh Keshavarzi, Brian O'Sullivan, Jolie Ringash, Andrew Hope, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, John Kim, John Waldron, Anna Spreafico, David P Goldst Head & Neck.2021; 43(2): 456. CrossRef
Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary C. Jillian Tsai, Thomas J. Galloway, Danielle N. Margalit, Richard L. Bakst, Beth M. Beadle, Jonathan J. Beitler, Steven Chang, Allen Chen, Jay Cooper, Shlomo A. Koyfman, John A. Ridge, Jared Robbins, Minh Tam Truong, Sue S. Yom, Farzan Siddiqui Head & Neck.2021; 43(1): 392. CrossRef
Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma Ali Hosni, Shao Hui Huang, Wei Xu, Jie Su, Erin Watson, Michael Glogauer, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, David P. Goldstein, John Waldron, John R. de Al Radiotherapy and Oncology.2021; 156: 95. CrossRef
Refining Guidelines Regarding Unilateral Treatment in Patients With Well-lateralized Squamous Cell Carcinoma of the Palatine Tonsil and Multiple Positive Nodes or Extranodal Extension Robert J. Amdur, Paul M. Harari, Peter T. Dziegielewski, William M. Mendenhall Practical Radiation Oncology.2021; 11(3): e247. CrossRef
Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck Sandra Nuyts, Heleen Bollen, Avrahram Eisbruch, June Corry, Primoz Strojan, Antti A. Mäkitie, Johannes A. Langendijk, William M. Mendenhall, Robert Smee, Remco DeBree, Anne W. M. Lee, Alessandra Rinaldo, Alfio Ferlito Head & Neck.2021; 43(9): 2807. CrossRef
The treatment of tonsillar squamous cell carcinoma at Hue Central Hospital Phuong Nam Tran Journal of Clinical Medicine- Hue Central Hospital.2021;[Epub] CrossRef
Efficacy of Postoperative Unilateral Neck Irradiation in Patients with Buccal Mucosa Squamous Carcinoma with Extranodal Extension: A Propensity Score Analysis Chia-Hsin Lin, Chien-Yu Lin, Kang-Hsing Fan, Sheng-Ping Hung, Yung-Chih Chou, Chia-Jen Liu, Wen-Chi Chou, Yen-Chao Chen, Shiang-Fu Huang, Chung-Jan Kang, Kai-Ping Chang, Hung-Ming Wang, Ann-Joy Cheng, Joseph Tung-Chieh Chang Cancers.2021; 13(23): 5997. CrossRef
Contralateral nodal failures in oropharyngeal cancers after TORS and unilateral neck management: A retrospective study Axel Sahovaler, John J. W. Lee, Wei Xu, Susie Su, Ali Hosni, Andrew Bayley, David P. Goldstein, John R. de Almeida Journal of Otolaryngology - Head & Neck Surgery.2021;[Epub] CrossRef
Lymphatic mapping with SPECT‐CT for evaluation of contralateral drainage in lateralized oropharyngeal cancers using an awake injection technique Carissa M. Thomas, Mohemmed N. Khan, Ravi Mohan, Aaron Hendler, Ali Hosni, Douglas B. Chepeha, David P. Goldstein, Richard M Cooper, John R. de Almeida Head & Neck.2020; 42(3): 385. CrossRef
Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoya Yokota International Journal of Clinical Oncology.2020; 25(2): 258. CrossRef
Désescalade thérapeutique dans les cancers de l’oropharynx induit par les HPV : mise au point C. Lahmamssi, J.-B. Guy, N. Benchekroun, Z. Bouchbika, N. Taoufik, H. Jouhadi, S. Sahraoui, A. Benider, M. Ben Mrad, O. Jmour, A. Bousarsar, M.L. Lan, Q. Lei, M. Benna, D. Moslemi, A. Vallard, N. Magné Cancer/Radiothérapie.2020; 24(3): 258. CrossRef
The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors Sonja Stieb, Ismael Perez-Martinez, Abdallah S.R. Mohamed, Stockton Rock, Nimit Bajaj, Tanaya S. Deshpande, Mohamed Zaid, Adam S. Garden, Ryan P. Goepfert, Richard Cardoso, Renata Ferrarotto, Jay P. Reddy, Jack Phan, William H. Morrison, David I. Rosentha Clinical and Translational Radiation Oncology.2020; 24: 71. CrossRef
Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? Yonca Onbasi, Sebastian Lettmaier, Markus Hecht, Sabine Semrau, Heinrich Iro, Marco Kesting, Rainer Fietkau, Marlen Haderlein Strahlentherapie und Onkologie.2019; 195(6): 482. CrossRef
Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update Julian Biau, Michel Lapeyre, Idriss Troussier, Wilfried Budach, Jordi Giralt, Cai Grau, Joanna Kazmierska, Johannes A. Langendijk, Mahmut Ozsahin, Brian O'Sullivan, Jean Bourhis, Vincent Grégoire Radiotherapy and Oncology.2019; 134: 1. CrossRef
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer Jared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, John N Lukens, Samuel Swisher-McClure, Gregory S Weinstein, Bert W O’Malley Jr, Ara A Chalian, Christopher H Rassekh, Jason G Newman, Roger B Cohen, Joshua M Bauml, Charu Aggarwal, Alexander Lin The British Journal of Radiology.2019;[Epub] CrossRef
Purpose
The purpose of this study was to evaluate the clinical outcomes of patients treated with radiotherapy (RT) for a carcinoma of the external auditory canal (EAC) and middle ear.
Materials and Methods
The records of 32 patients who received RT from 1990 to 2013 were reviewed retrospectively. The Pittsburgh classification was used to stage all the cancers (early stage, T1/T2 [n=12]; advanced stage, T3/T4 or N positive [n=20]). Twenty-one patients (65.6%) were treated with postoperative RT and 11 patients (34.4%) were treated with definitive RT. The median radiation doses for postoperative and definitive RT were 60 Gy and 64.8 Gy, respectively. Chemotherapy was administered to seven patients (21.9%).
Results
The 5-year overall survival and disease-free survival rates for all patients were 57% and 52%, respectively. The disease control rates for the patients with early stage versus advanced stage carcinomawere 55.6% (5/9) and 50% (6/12) in the postoperative RT group and 66.7% (2/3) and 37.5% (3/8) in the definitive RT group, respectively. Overall, 15 cases (14 patients, 46.7%) experienced treatment failure; these failures were classified as local in four cases, regional in one case, and distant in 10 cases. The median follow-up period after RT was 51 months (range, 7 to 286 months).
Conclusion
Patients with early stage carcinoma achieved better outcomes when definitive RT was used. Advanced stage carcinoma patients experienced better outcomes with postoperative RT. The high rate of distant failure after RT, with or without surgery, reflected the lack of a consensus regarding the best therapeutic approach for treating carcinoma of the EAC and middle ear.
Citations
Citations to this article as recorded by
Survival Outcomes of Temporal Bone Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis Krystelle Sioufi, Aaron David Haynes, Paul W. Gidley, Anastasios Maniakas, Dianna Roberts, Marc‐Elie Nader Otolaryngology–Head and Neck Surgery.2024; 171(1): 1. CrossRef
The international expert consensus on management of external auditory canal carcinoma Pei Zhou, Rubens de Brito, Yong Cui, Simon Lloyd, Henricus Kunst, J. Walter Kutz, Navin Mani, In Seok Moon, Badr Eldin Mostafa, Cindy Nabuurs, Sampath Chandra Prasad Rao, Bingbin Xie, Yibo Zhang, Chunfu Dai European Archives of Oto-Rhino-Laryngology.2024;[Epub] CrossRef
Postoperative Radiotherapy for pT1- and pT2-Classified Squamous Cell Carcinoma of the External Auditory Canal Cindy Nabuurs, Wietske Kievit, Charles Leemans, Conrad Smit, Michiel van den Brekel, Robert Pauw, Bernard van der Laan, Jeroen Jansen, Martin Lacko, Weibel Braunius, Chunfu Dai, Xunbei Shi, Giovanni Danesi, Jan Bouček, Daniele Borsetto, Shravan Gowrishank Cancers.2024; 16(23): 4026. CrossRef
Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience Yongbo Zheng, Ke Qiu, Yangju Fu, Wenjie Yang, Danni Cheng, Yufang Rao, Minzi Mao, Yao Song, Wei Xu, Jianjun Ren, Yu Zhao Cancer Medicine.2023; 12(5): 5304. CrossRef
Analysis of Prognostic Factors For External Auditory Canal Carcinoma: A 22‐Year Experience Isabelle J. H. Jang, Jiun Fong Thong, Constance E. H. Teo, Kiattisa Sommat The Laryngoscope.2023; 133(9): 2203. CrossRef
Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma Meng-wen Shi, Jing Huang, Yu Sun Current Medical Science.2023; 43(2): 213. CrossRef
Preoperative simulation using three‐dimensional printer in four temporal bone surgeries Ichiro Fukumoto, Yukiyoshi Mita, Rie Shimmi, Yuri Sonobe, Tomohisa Iinuma, Kazuki Yamasaki, Shuji Yonekura, Toshimitsu Nemoto, Toyoyuki Hanazawa Clinical Case Reports.2023;[Epub] CrossRef
The Efficacy of Radiotherapy without Surgery for External Auditory Canal Squamous Cell Carcinoma Naoto Osu, Atsushi Musha, Hikaru Yumisaki, Kohei Okada, Nobuteru Kubo, Naoko Okano, Yukihiko Takayasu, Masato Shino, Osamu Nikkuni, Shota Ida, Hidemasa Kawamura, Kazuaki Chikamatsu, Tatsuya Ohno Journal of Clinical Medicine.2022; 11(19): 5905. CrossRef
Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma Ke Qiu, Wendu Pang, Jianqing Qiu, Junhong Li, Danni Cheng, Yufang Rao, Yijun Dong, Minzi Mao, Qiurui Liu, Xiaosong Mu, Wei Zhang, Wei Xu, Jianjun Ren, Yu Zhao Cancer Medicine.2021; 10(22): 7958. CrossRef
Evaluation of the modified Pittsburgh classification for predicting the disease‐free survival outcome of squamous cell carcinoma of the external auditory canal Cindy H. Nabuurs, Wietske Kievit, Nilou Labbé, C. René Leemans, Conrad F. G. M. Smit, Michiel W. M. van den Brekel, Robert J. Pauw, Bernard F. A. M. van der Laan, Jeroen C. Jansen, Martin Lacko, Weibel W. Braunius, Shinya Morita, Małgorzata Wierzbicka, Ta Head & Neck.2020; 42(12): 3609. CrossRef
Management of Temporal Bone Malignancy in Ireland Robbie S. R. Woods, Anel Naude, John Barry O'Sullivan, Daniel Rawluk, Mohsen Javadpour, Peter Walshe, Peter D. Lacy, James Paul O'Neill, Rory McConn-Walsh Journal of Neurological Surgery Part B: Skull Base.2020; 81(06): 680. CrossRef
A retrospective multicenter study of carbon‐ion radiotherapy for external auditory canal and middle ear carcinomas Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun‐ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, Kenji Nemoto, Takashi Nakano, Tadashi Kamada Cancer Medicine.2019; 8(1): 51. CrossRef
Squamous cell carcinoma of the temporal bone: A current review Benjamin D. Lovin, Paul W. Gidley Laryngoscope Investigative Otolaryngology.2019; 4(6): 684. CrossRef
Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee
Cancer Res Treat. 2016;48(1):425-425. Published online January 10, 2016
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Cho, Chul Seung Kay, Yeon-Sil Kim
Cancer Res Treat. 2016;48(3):917-927. Published online December 28, 2015
Purpose We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed.
Results After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.
Citations
Citations to this article as recorded by
Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma Yihong Lin, Xiongbin Yu, Linbin Lu, Hong Chen, Junxian Wu, Yaying Chen, Qin Lin, Xuewen Wang, Xi Chen, Xiong Chen Cancer Biomarkers.2023; 37(1): 1. CrossRef
Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis Shan-Shan Yang, Jian-Gui Guo, Jia-Ni Liu, Zhi-Qiao Liu, En-Ni Chen, Chun-Yan Chen, Pu-Yun OuYang, Fei Han, Fang-Yun Xie Frontiers in Oncology.2021;[Epub] CrossRef
Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies Minmin Li, Bin Zhang, Qiuying Chen, Lu Zhang, Xiaokai Mo, Zhuozhi Chen, Zhe Jin, Luyan Chen, Jingjing You, Shuixing Zhang Head & Neck.2021; 43(6): 1912. CrossRef
Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy Youping Xiao, Ying Chen, Yunbin Chen, Zhuangzhen He, Yiqi Yao, Jianji Pan Cancer Research and Treatment.2019; 51(1): 345. CrossRef
Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management Yong Chan Ahn Radiation Oncology Journal.2019; 37(2): 67. CrossRef
A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma Pu-Yun OuYang, Xiao-Min Zhang, Xing-Sheng Qiu, Zhi-Qiao Liu, Lixia Lu, Yuan-Hong Gao, Fang-Yun Xie The Oncologist.2019; 24(4): 505. CrossRef
Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis Teng Hwee Tan, Yu Yang Soon, Timothy Cheo, Francis Ho, Lea Choung Wong, Jeremy Tey, Ivan W.K. Tham Radiotherapy and Oncology.2018; 129(1): 10. CrossRef
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma Jiraporn Setakornnukul, Kullathorn Thephamongkhol BMC Cancer.2018;[Epub] CrossRef
TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series N. Toumi, W. Ben Kridis, W. Mnejja, R. Bouzguenda, A. Khanfir, A. Ghorbel, J. Daoud, M. Frikha Cancer/Radiothérapie.2018; 22(3): 216. CrossRef
Does concurrent chemoradiotherapy preceded by chemotherapy improve survival in locally advanced nasopharyngeal cancer patients? Experience from Ghana Joel Yarney, Naa A. Aryeetey, Alice Mensah, Emmanuel D. Kitcher, Verna Vanderpuye, Charles Aidoo, Kenneth Baidoo Cancers of the Head & Neck.2017;[Epub] CrossRef
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis Mei Lan, Chunyan Chen, Ying Huang, Li Tian, Zhijun Duan, Fei Han, Junfang Liao, Meiling Deng, Terence T. Sio, Anussara Prayongrat, Lie Zheng, Shaoxiong Wu, Taixiang Lu Scientific Reports.2017;[Epub] CrossRef
A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma H. M. Li, P. Li, Y. J. Qian, X. Wu, L. Xie, F. Wang, H. Zhang, L. Liu BMC Cancer.2016;[Epub] CrossRef
Purpose
We investigated 18F-fluorodeoxyglucose positron emission tomography (PET)-derived parameters as prognostic indices for disease progression and survival in locally advanced nasopharyngeal carcinoma (NPC) and the effect of high-dose radiotherapy for a subpopulation with PET-based poor prognoses.
Materials and Methods
Ninety-seven stage III and Iva-b NPC patients who underwent definitive treatment and PET were reviewed. For each primary, nodal, and whole tumor, maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) were evaluated.
Results
Based on the C-index (0.666) and incremental area under the curve (0.669), the whole tumor TLGwas the most useful predictorfor progression-free survival (PFS); thewhole tumor TLG cut-off value showing the best predictive performance was 322.7. In multivariate analysis, whole tumor TLG was a significant prognostic factor for PFS (hazard ratio [HR], 0.3; 95% confidence interval [CI], 0.14 to 0.65; p=0.002) and OS (HR, 0.29; 95% CI, 0.11 to 0.79; p=0.02). Patients with low whole tumor TLG showed the higher 5-year PFS in the subgroup for only patients receiving intensity modulated radiotherapy (77.4% vs. 53.0%, p=0.01). In the subgroup of patients with high whole tumor TLG, patients receiving an EQD2 ≥ 70 Gy showed significantly greater complete remission rates (71.4% vs. 33.3%, p=0.03) and higher 5-year OS (74.7% vs. 19.6%, p=0.02).
Conclusion
Our findings demonstrated that whole tumor TLG could be an independent prognostic factor and high-dose radiotherapy could improve outcomes for NPC showing high whole tumor TLG.
Citations
Citations to this article as recorded by
Clinical significance of post-chemoradiotherapy 2-[18F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study Yiwen Mo, Yuan Wei, Liping Liang, Tingfan Wu, Xinling Li, Ruping Li, Wei Fan, Yingying Hu, Xu Zhang Oral Oncology.2025; 161: 107160. CrossRef
Predictive significance of pretreatment 18F‐FDG PET volumetric parameters on survival outcomes in pediatric patients with locally advanced undifferentiated nasopharyngeal carcinoma Gihan El‐Hennawy, Salma ElMenawi, Eman Nasr Said, Wael Zekri, Mohamed Zaghloul, Ahmed Mustafa Abd Elsalam, Habiba El‐Fendy, Ismail Elantably Pediatric Blood & Cancer.2024;[Epub] CrossRef
The prognostic value of the ratio of standard uptake value of lymph node to primary tumor before treatment of locally advanced nasopharyngeal carcinoma Yunlong Lou, Dandan Chen, Zheng Lin, Jianda Sun, Li Song, Wenzhong Chen, Ming Zhang, Yibiao Chen European Archives of Oto-Rhino-Laryngology.2023; 280(1): 347. CrossRef
Strategy to minimize induced 24Na, 56Mn activity in concrete composites used for fast neutron shielding: impact of cement and rock aggregates A. A. Shanbhag, Sabyasachi Paul, S. C. Sharma, M. S. Kulkarni Journal of Radioanalytical and Nuclear Chemistry.2023; 332(8): 3093. CrossRef
Prognostic value of primary tumor and lymph node volumetric metabolic parameters at pre-treatment F-18 FDG PET/CT in nasopharyngeal carcinoma Bedriye Büşra Demirel, Seda Gülbahar Ateş, Ebru Atasever Akkaş, Fatih Göksel, Gülin Uçmak Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2023; 42(6): 367. CrossRef
Valor pronóstico de los parámetros metabólicos volumétricos del tumor primario y ganglios linfáticos en el PET/TC pretratamiento en el carcinoma nasofaríngeo B.B. Demirel, S. Gülbahar Ateş, E. Atasever Akkaş, F. Göksel, G. Uçmak Revista Española de Medicina Nuclear e Imagen Molecular.2023; 42(6): 367. CrossRef
The role of PET/CT in radiotherapy for nasopharyngeal carcinoma Hongjia Li, Ziren Kong, Yongbo Xiang, Rong Zheng, Shaoyan Liu Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature Chi Leung Chiang, Qiaojuan Guo, Wai Tong Ng, Shaojun Lin, Tiffany Sze Wai Ma, Zhiyuan Xu, Youping Xiao, Jishi Li, Tianzhu Lu, Horace Cheuk Wai Choi, Wenqi Chen, Eric Sze Chun Chau, Peter Ho Yin Luk, Shao Hui Huang, Brian O’Sullivan, Jianji Pan, Anne Wing Frontiers in Oncology.2021;[Epub] CrossRef
Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma Yu-Hung Chen, Kai-Ping Chang, Sung-Chao Chu, Tzu-Chen Yen, Ling-Yi Wang, Joseph Tung-Chieh Chang, Cheng-Lung Hsu, Shu-Hang Ng, Shu-Hsin Liu, Sheng-Chieh Chan European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(3): 650. CrossRef
Applied nuclear physics at the new high-energy particle accelerator facilities Marco Durante, Alexander Golubev, Woo-Yoon Park, Christina Trautmann Physics Reports.2019; 800: 1. CrossRef
Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis Jie Lin, Guozhu Xie, Guixiang Liao, Baiyao Wang, Miaohong Yan, Hui Li, Yawei Yuan Oncotarget.2017; 8(20): 33884. CrossRef
Purpose The purpose of this study is to assess the utility of positron emission tomography (PET) for predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with mastectomy. Materials and Methods Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109 had undergone preoperative 18F-fluorodeoxyglucose/PET and were included. Metabolic (maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]), and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values were analyzed and compared with clinical outcome.
Results At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was 95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained an independent risk factor for RFS (p=0.006). Using the method of Contal and O’Quigley, a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based highrisk group (≥ 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both breast and nodes). The prognosis was much worse when high SUVmax (≥ 5.36) was detected in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had increased risk of locoregional recurrence when compared to the low-risk group (p=0.037). Conclusion High SUVmax on preoperative PET showed association with elevated risk of locoregional recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence risk and clarify indications for post-mastectomy radiotherapy in this subset of patients.
Citations
Citations to this article as recorded by
Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy Soong June Bae, Sung Gwe Ahn, Jung Hwan Ji, Chih Hao Chu, Dooreh Kim, Janghee Lee, Soeun Park, Chihwan Cha, Joon Jeong Journal of Breast Cancer.2022; 25(6): 485. CrossRef
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy Tomoko Higuchi, Yukie Fujimoto, Hiromi Ozawa, Ayako Bun, Reiko Fukui, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Koichiro Yamakado, Yasuo Miyoshi Annals of Surgical Oncology.2019; 26(7): 2175. CrossRef
The ability of pre-treatment F-18 FDG PET/CT metabolic parameters for predicting axillary lymph node and distant metastasis and overall survival Burcak Yilmaz, Sedef Dağ, Nurhan Ergul, Tevfik Fikret Çermik Nuclear Medicine Communications.2019; 40(11): 1112. CrossRef
Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes – Past, present and future Filip Kaššák, Christine Rossier, Cristina Picardi, Jacques Bernier The Breast.2019; 48: 73. CrossRef
The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer Wei Diao, Fangfang Tian, Zhiyun Jia European Journal of Radiology.2018; 105: 1. CrossRef
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer Seo Hee Choi, Jee Suk Chang, Ja Seung Koo, Jong Won Park, Joo Hyuk Sohn, Ki Chang Keum, Chang-Ok Suh, Yong Bae Kim American Journal of Clinical Oncology.2018; 41(11): 1049. CrossRef
Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer Yong-il Kim, Yong Joong Kim, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung, Keon Wook Kang European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(11): 1787. CrossRef
Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers Arisa Nishimukai, Natsuko Inoue, Ayako Kira, Masashi Takeda, Koji Morimoto, Kazuhiro Araki, Kazuhiro Kitajima, Takahiro Watanabe, Seiichi Hirota, Toyomasa Katagiri, Shoji Nakamori, Kouhei Akazawa, Yasuo Miyoshi, Renato Franco PLOS ONE.2017; 12(9): e0184508. CrossRef
Prognostic Value of SUVmax of <sup>18</sup>F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis Ryusuke Murakami, Yoshimitsu Fukushima, Hitomi Tani, Kotomi Iwata, Shinichiro Kumita, Maki Nakai, Tomoko Kurita, Keiko Yanagihara, Hiroyuki Takei, Miyuki Matsubara Open Journal of Medical Imaging.2017; 07(03): 112. CrossRef
Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis Young-Sil An, Doo Kyoung Kang, Yongsik Jung, Tae Hee Kim Medicine.2017; 96(45): e8557. CrossRef
Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era Jee Suk Chang, Jung Eun Choi, Min Ho Park, Sung Hoo Jung, Byung Ock Choi, Hyung Seok Park, Seho Park, Yong Bae Kim Medicine.2016; 95(19): e3592. CrossRef
Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes Tomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa, Yukie Fujimoto, Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Kitajima, Kazuhito Fukushima, Yasuo Miyoshi The Breast.2016; 30: 5. CrossRef
Purpose
The purpose of this study is to investigate the prognostic significance of SOX2 gene amplification and expression in patients with American Joint Committee on Cancer stage III lung squamous cell carcinoma (SCC) who underwent surgery followed by adjuvant radiotherapy.
Materials and Methods
Pathological specimens were obtained from 33 patients with stage III lung SCC treated with surgery followed by adjuvant radiotherapy between 1996 and 2008. SOX2 gene amplification and protein expression were analyzed using fluorescent in situ hybridization and immunohistochemistry, respectively. Patients were divided into two groups according to their SOX2 gene amplification and protein expression status. Kaplan-Meier estimates and a Cox proportional hazards model were used to identify the prognostic factors affecting patient survival.
Results
The median follow-up period for surviving patientswas 58 months (range, 5 to 102 months). SOX2 gene amplification was observed in 22 patients and protein overexpression in 26 patients. SOX2 overexpression showed significant association with SOX2 gene amplification (p=0.002). In multivariate analysis, SOX2 overexpression was a significant prognostic factor for overall survival (OS) (hazard ratios [HR], 0.1; 95% confidence interval [CI], 0.002 to 0.5; p=0.005) and disease-free survival (DFS) (HR, 0.15; 95% CI, 0.04 to 0.65; p=0.01). Age (HR, 0.33; 95% CI, 0.11 to 0.98; p=0.046) and total radiation dose (HR, 0.13; 95% CI, 0.02 to 0.7; p=0.02) were the independent prognostic factors for OS and DFS. Patients with SOX2 amplification did not show a longer OS (p=0.95) and DFS (p=0.48).
Conclusion
Our data suggested that SOX2 overexpression could be used as a positive prognostic factor in patients with stage III lung SCC receiving adjuvant radiotherapy.
Citations
Citations to this article as recorded by
Identifying the key hub genes linked with lung squamous cell carcinoma by examining the differentially expressed and survival genes Anushka Pravin Chawhan, Norine Dsouza Molecular Genetics and Genomics.2024;[Epub] CrossRef
Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay Taesung Jeon, Uk Jeen Oh, Jaeyoung Min, Chungyeul Kim Thoracic Cancer.2023; 14(26): 2635. CrossRef
The role of SOX family members in solid tumours and metastasis Daniela Grimm, Johann Bauer, Petra Wise, Marcus Krüger, Ulf Simonsen, Markus Wehland, Manfred Infanger, Thomas J. Corydon Seminars in Cancer Biology.2020; 67: 122. CrossRef
Blood-Based SOX2-Promoter Methylation in Relation to Exercise and PM2.5 Exposure among Taiwanese Adults Chun-Lang Su, Disline Manli Tantoh, Ying-Hsiang Chou, Lee Wang, Chien-Chang Ho, Pei-Hsin Chen, Kuan-Jung Lee, Oswald Ndi Nfor, Shu-Yi Hsu, Wen-Miin Liang, Yung-Po Liaw Cancers.2020; 12(2): 504. CrossRef
Epithelial-Mesenchymal Transition in Skin Cancers: A Review Anastasia Hodorogea, Andreea Calinescu, Mihaela Antohe, Mihaela Balaban, Roxana Ioana Nedelcu, Gabriela Turcu, Daniela Adriana Ion, Ioana Anca Badarau, Catalin Mihai Popescu, Raluca Popescu, Cristiana Popp, Mirela Cioplea, Luciana Nichita, Ionela Hulea, A Analytical Cellular Pathology.2019; 2019: 1. CrossRef
Towards understanding the mechanisms of actions of carcinoembryonic antigen‐related cell adhesion molecule 6 in cancer progression Balsam Rizeq, Zain Zakaria, Allal Ouhtit Cancer Science.2018; 109(1): 33. CrossRef
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells Ugo Testa, Germana Castelli, Elvira Pelosi Cancers.2018; 10(8): 248. CrossRef
SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1‑mediated PI3K/AKT signaling pathway Zhuo‑Ran Li, Yong Jiang, Jian‑Zhong Hu, Yang Chen, Quan‑Zhong Liu Oncology Letters.2018;[Epub] CrossRef
Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis Qingbao Li, Fang Liu, Yuan Zhang, Lei Fu, Cong Wang, Xuan Chen, Shanghui Guan, Xiangjiao Meng Oncotarget.2016; 7(23): 34520. CrossRef
Purpose
The purpose of this study is to compare the treatment outcomes for locally advanced resectable hypopharyngeal cancer between organ-preserving chemoradiotherapy (CRT) and surgery followed by radiotherapy (SRT).
Materials and Methods
We reviewed 91 patients with stage III/IV hypopharyngeal squamous cell carcinoma treated with radiotherapy (RT). In the CRT group (n=34), 18 patients were treated with concurrent CRT and 16 patients with induction chemotherapy plus concurrent CRT. In the SRT group (n=57), six patients were treated with total laryngopharyngectomy, 34 patients with total laryngectomy (TL) and partial pharyngectomy (PP), and 17 patients with PP, which were followed by adjuvant radiotherapy (n=41) or CRT (n=16). The median RT dose was 70 Gy for CRT and 59.4 Gy for SRT.
Results
Five-year local control (84.1% vs. 90.9%), and disease-free survival (DFS, 51.0% vs. 52.7%) and overall survival (OS, 58.6% vs. 56.6%) showed no significant difference between the CRT and SRT groups. The functional larynx-preservation rate was higher in the CRT group (88.2% vs. 29.8%). Treatment-related toxicity, requiring surgical intervention, occurred more frequently in the SRT group (37% vs. 12%). In the SRT group, TL resulted in a significantly higher DFS than larynx-sparing surgery (63.9% vs. 26.5%, p=0.027). Treatment outcome of the SRT group improved when only patients with TL were considered (n=40); however, 5-year OS (67.1% vs. 58.6%, p=0.830) and DFS (63.9% vs. 51.0%, p=0.490) did not improve significantly when compared to the CRT group.
Conclusion
Organ preserving CRT provided a treatment outcome that is comparable to SRT for locally advanced hypopharyngeal cancer, while offering an opportunity for functional larynx-preservation and reduced treatment-related toxicity.
Citations
Citations to this article as recorded by
Prognostic Factors and Long-Term Outcome Prediction in Patients with Hypopharyngeal Carcinoma Treated with (Chemo)radiotherapy: Development of a Prognostic Model Miloslav Pala, Pavla Novakova, Adam Tesar, Lucie Vesela, Antonin Vrana, Jarmila Sukova, Zdenka Pechacova, Petra Holeckova, Tereza Drbohlavova, Tomas Podlesak, Petra Tesarova Biomedicines.2025; 13(2): 417. CrossRef
Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation Pei Yuan Fong, Thomas Kwok Seng Loh, Liang Shen, Donovan Kum Chuen Eu, Chwee Ming Lim European Archives of Oto-Rhino-Laryngology.2024; 281(5): 2645. CrossRef
Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment Yu-Hsuan Lin, Jenn-Ren Hsiao, Yuan-Hua Wu, Jeffrey S. Chang, Chun-Yen Ou, Wei-Ting Lee, Cheng-Chih Huang, Chan-Chi Chang, Yu-Hsuan Lai, Sen-Tien Tsai, Wei-Ting Hsueh, Chia-Jui Yen, Chen-Lin Lin, Yu-Shan Chen, Shih-Sheng Jiang, Yu-Chu Su, Shang-Yin Wu Annals of Surgical Oncology.2023; 30(2): 1169. CrossRef
Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma Tian-Yun Lin, Tsung-Lun Lee, Yen-Bin Hsu, Shyh-Kuan Tai, Ling-Wei Wang, Muh-Hwa Yang, Pen-Yuan Chu Frontiers in Oncology.2023;[Epub] CrossRef
Optimal treatment strategy and prognostic analysis for hypopharyngeal squamous-cell carcinoma patients with T3-T4 or node-positive: A population-based study Linhui Zheng, Sha Fang, Linfeng Ye, Wenqi Cai, Wenbin Xiang, Yan Qi, Huachao Wu, Chunqian Yang, Runze Zhang, Yifeng Liu, Yue Liu, Chaoyan Wu, Haijun Yu European Journal of Surgical Oncology.2023; 49(7): 1162. CrossRef
Study on the treatment outcomes of advanced laryngeal and hypopharyngeal cancer with induction chemotherapy Hideoki Uryu, Shingo Tamura, Rina Kitagawa, Ayaka Koide, Kaori Hara, Ryutaro Uchi, Torahiko Nakashima Toukeibu Gan.2023; 49(3): 249. CrossRef
Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment Donghyeok Kim, Nalee Kim, Sungmin Koh, Man Ki Chung, Young-Ik Son, Dongryul Oh, Han-Sin Jeong, Yong Chan Ahn Cancer Research and Treatment.2022; 54(1): 84. CrossRef
The impact of physician’s characteristics on decision-making in head and neck oncology: Results of a national survey Emilien Chabrillac, Sébastien Lamy, Pascale Grosclaude, Fanny Cros, Benjamin Vairel, Jérôme Sarini, Sébastien Vergez, Antoine Nebout, Pierre Bories, Agnès Dupret-Bories Oral Oncology.2022; 129: 105895. CrossRef
Posttreatment Non-Improved Vocal Cord Mobility Indicates the Need of Salvage Surgery for Hypopharyngeal Carcinomas Yu-qin He, Xi-wei Zhang, Yi-ming Zhu, Xiao-guang Ni, Ze-hao Huang, Chang-ming An, Jun-lin Yi, Shao-yan Liu Frontiers in Oncology.2021;[Epub] CrossRef
Tumor dimension‐dependent microscopic extensions of hypopharyngeal cancer: Therapeutic implications for larynx‐preserving hypopharyngectomy Joongbo Shin, Jiyeon Lee, Nayoung Hwang, Sung Yong Choi, Woori Park, Nayeon Choi, Young‐Ik Son, Junhun Cho, Han‐Sin Jeong Journal of Surgical Oncology.2021; 123(4): 872. CrossRef
Survival and complications with a surgical approach in advanced hypopharyngeal cancer Maria Paz Galeano Machuca, Deborah L. Ng, Shyuang‐Der Terng, Wen‐Ching Wu, Chih‐Tao Cheng Journal of Surgical Oncology.2021; 123(7): 1540. CrossRef
High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer Jialing Wu, Kaiyun You, Changlong Chen, Huimin Zhong, Yanhui Jiang, Huaqian Mo, Juanjuan Song, Xingsheng Qiu, Yimin Liu Frontiers in Oncology.2021;[Epub] CrossRef
Matched-Pair Analysis of Survival in the Patients with Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Treated with Induction Chemotherapy Plus Chemo-Radiation or Total Laryngectomy Patricia García-Cabo, Fernando López, Mario Sánchez-Canteli, Laura Fernández-Vañes, César Álvarez-Marcos, José Luis Llorente, Maria Ángeles de la Rúa, Pilar Blay, Juan P. Rodrigo Cancers.2021; 13(7): 1735. CrossRef
Physician practice variation in head and neck cancer therapy: Results of a national survey Fanny Cros, Sébastien Lamy, Pascale Grosclaude, Antoine Nebout, Emilien Chabrillac, Sébastien Vergez, Pierre Bories, Agnès Dupret-Bories Oral Oncology.2021; 117: 105293. CrossRef
Survival Benefits From Surgery for Stage IVa Head and Neck Squamous Cell Carcinoma: A Multi-Institutional Analysis of 1,033 Cases Jun-Ook Park, Young Min Park, Woo-Jin Jeong, Yoo Seob Shin, Yong Tae Hong, Ik Joon Choi, Ji Won Kim, Seung Hoon Woo, Yeon Soo Kim, Jae Won Chang, Min-Sik Kim, Kwang-Yoon Jung, Soon-Hyun Ahn, Chul-Ho Kim, Ki Hwan Hong, Phil-Sang Chung, Young-Mo Kim, Se-Heo Clinical and Experimental Otorhinolaryngology.2021; 14(2): 225. CrossRef
Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer Nina Burbure, Elizabeth Handorf, John A. Ridge, Jessica Bauman, Jeffrey C. Liu, Anshu Giri, Thomas J. Galloway Head & Neck.2021; 43(10): 3042. CrossRef
Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis Jie Cui, Liping Wang, Jinsong Piao, Haiyan Huang, Weiquan Chen, Zhen Chen, Hong Yang, Xiaojun Tan, Jiansheng Li, Genglong Liu International Journal of Surgery.2020; 82: 249. CrossRef
lncRNA HOXA11-AS Promotes Proliferation and Migration via Sponging miR-155 in Hypopharyngeal Squamous Cell Carcinoma Jianing Xu, Qiyu Bo, Xiang Zhang, Dapeng Lei, Jue Wang, Xinliang Pan Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2020; 28(3): 311. CrossRef
Pacientes con carcinoma localmente avanzado de hipofaringe. Resultados a lo largo de un periodo de 30 años Xavier León, Montserrat López, Jacinto García, Carlota Rovira, María Casasayas, Miquel Quer Acta Otorrinolaringológica Española.2019; 70(6): 315. CrossRef
A Survival Analysis of Hypopharyngeal Cancer Patients: A Hospital-Cancer registry Based Study Manigreeva Krishnatreya, Amal Chandra Kataki, Jagannath Dev Sharma, Nizara Baishya, Tashnin Rahman, Mouchumee Bhattcharyya, Ashok Kumar Das, Manoj Kalita Indian Journal of Otolaryngology and Head & Neck Surgery.2019; 71(S1): 798. CrossRef
Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases Eun-Jae Chung, Woo-Jin Jeong, Young Ho Jung, Seong Keun Kwon, Tack-Kyun Kwon, Soon-Hyun Ahn, Myung-Whun Sung, Bhumsuk Keam, Dae-Seog Heo, Jin Ho Kim, Hong-Gyun Wu, Keun-Wook Lee, Keun-Yong Eom, Young-Soo Rho Oral Oncology.2019; 89: 84. CrossRef
Surgery is not the only determinant of an outcome in patients with hypopharyngeal carcinoma Robert Smee, Janet R. Williams, Damian P. Kotevski Head & Neck.2019; 41(5): 1165. CrossRef
Open-neck organ preservation surgery for hypopharyngeal cancer: indications, techniques, limits, and outcomes Patrick J. Bradley, Liangfa Liu Current Opinion in Otolaryngology & Head & Neck Surgery.2019; 27(2): 123. CrossRef
Oncologic and Functional Outcomes After Primary and Salvage Laryngopharyngoesophagectomy With Gastric Pull-Up Reconstruction for Locally Advanced Hypopharyngeal Squamous Cell Carcinoma Jeroen Meulemans, Floor Couvreur, Eline Beckers, Philippe Nafteux, Hans Van Veer, Vincent Vander Poorten, Pierre Delaere, Willy Coosemans Frontiers in Oncology.2019;[Epub] CrossRef
Patients With Locally Advanced Hypopharyngeal Carcinoma. Results Over a 30-year Period Xavier León, Montserrat López, Jacinto García, Carlota Rovira, María Casasayas, Miquel Quer Acta Otorrinolaringologica (English Edition).2019; 70(6): 315. CrossRef
Clinical value of ultrasonic imaging in diagnosis of hypopharyngeal cancer with cervical lymph node metastasis Guzi Wang, Xiaoguang Li, Li Li, Dayu Liu, Ruijie Sun, Qiu Zhang, Chenchen Geng, Haitong Gong, Xiaoqian Gao Oncology Letters.2019;[Epub] CrossRef
Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments A Habib The Journal of Laryngology & Otology.2018; 132(5): 385. CrossRef
Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population‐based study Yi‐Jun Kim, Rena Lee Cancer Medicine.2018; 7(12): 5889. CrossRef
The impact of surgical margin status on the outcomes of locally advanced hypopharyngeal squamous cell carcinoma treated by primary surgery Min Li, Ming Xie, Liang Zhou, Shuyi Wang Acta Oto-Laryngologica.2018; 138(12): 1136. CrossRef
The diagnostic role of diffusion-weighted magnetic resonance imaging in hypopharyngeal carcinoma Si‑Cong Zhang, Shui‑Hong Zhou, De‑Sheng Shang, Yang‑Yang Bao, Ling‑Xiang Ruan, Ting‑Ting Wu Oncology Letters.2018;[Epub] CrossRef
Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy Shigemichi Iwae, Masato Fujii, Ryuichi Hayashi, Yasuhisa Hasegawa, Takashi Fujii, Kenji Okami, Akihiro Homma, Tetsuro Onitsuka, Takakuni Kato, Takenori Ogawa, Kyoichi Terao, Nobuya Monden, Naoki Otsuki, Hiroshi Nishino, Ichiro Ota, Yasushi Fujimoto, Kazut International Journal of Clinical Oncology.2017; 22(6): 1001. CrossRef
Survival benefit of surgical approach for advanced oropharyngeal and hypopharyngeal cancer: A retrospective analysis Chih-Tao Cheng, Ching-Yuan Lin, Skye Hung-Chun Cheng, Yi-Ping Lin, Lay-Chin Lim, Nicolas Pennarun, Zhen-Ying Liu, Shyuang-Der Terng Head & Neck.2017; 39(10): 2104. CrossRef
When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma? William M. Mendenhall, Primož Strojan, Avraham Eisbruch, Robert Smee, Alessandra Rinaldo, Alfio Ferlito European Archives of Oto-Rhino-Laryngology.2015; 272(10): 2583. CrossRef
Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee
Cancer Res Treat. 2015;47(4):871-878. Published online February 13, 2015
Purpose To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. Materials and Methods From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy).
Results Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last followup, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. Conclusion Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.
Citations
Citations to this article as recorded by
Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study Fang Wang, Lu Zhou, Li-Jun Zhang, Chang-Bin Xie, Zhi-Wei Liao, Xiao-Dan Lin, Yue-Feng Wen Radiotherapy and Oncology.2024; 191: 110081. CrossRef
A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang, Xiao-Dong Zhu Frontiers in Oncology.2022;[Epub] CrossRef
MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma Yang Liu, Jianghu Zhang, Jingbo Wang, Runye Wu, Xiaodong Huang, Kai Wang, Yuan Qu, Xuesong Chen, Yexiong Li, Ye Zhang, Junlin Yi Radiology and Oncology.2022; 56(4): 479. CrossRef
The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma Xin-Bin Pan, Ling Li, Song Qu, Long Chen, Shi-Xiong Liang, Xiao-Dong Zhu Oral Oncology.2020; 101: 104520. CrossRef
Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study Di‐Han Liu, Xiao‐Yu Zhou, You‐Guang Pan, Si Chen, Zheng‐Hao Ye, Gang‐Dong Chen Cancer Medicine.2020; 9(4): 1287. CrossRef
Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update Ting Jin, Qun Zhang, Dong-Hua Luo, Feng Jiang, Qi-Feng Jin, Yuan-Yuan Chen, Xiao-Zhong Chen, Wei-Min Mao Translational Oncology.2020; 13(1): 25. CrossRef
Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Xiao-Dong Zhu Medicine.2019; 98(7): e14512. CrossRef
The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database Zaheer Ahmed, Lara Kujtan, Kevin Kennedy, Valerie Wood, David Schomas, Janakiraman Subramanian Cancer Medicine.2019; 8(4): 1500. CrossRef
Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study Xue-Song Sun, Di-Han Liu, Sai-Lan Liu, Qiu-Yan Chen, Shan-Shan Guo, Yue-Feng Wen, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Jin-Jie Yan, Ming-Huang Hong, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai Cancer Research and Treatment.2019; 51(4): 1449. CrossRef
Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature Sufang Wang, Shan Li, Liangfang Shen Current Problems in Cancer.2018; 42(3): 302. CrossRef
The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era Pei-Jing Li, Hao-Yuan Mo, Dong-Hua Luo, Wei-Han Hu, Ting Jin Oral Oncology.2018; 85: 95. CrossRef
Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Jia-Lin Ma, Song Qu, Ling Li, Long Chen, Xiao-Dong Zhu Oncotarget.2017; 8(8): 14029. CrossRef
Chemotherapy use and survival in stage II nasopharyngeal carcinoma Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Xiao-Dong Zhu Oncotarget.2017; 8(60): 102573. CrossRef
Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era Qiaojuan Guo, Tianzhu Lu, Shaojun Lin, Jingfeng Zong, Zhuhong Chen, Xiaofei Cui, Yu Zhang, Jianji Pan Japanese Journal of Clinical Oncology.2016; 46(3): 241. CrossRef
Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma Kai-Hua Chen, Xiao-Dong Zhu, Ling Li, Song Qu, Zhen-Qiang Liang, Xia Liang, Xin-Bin Pan, Zhong-Guo Liang, Yan-Ming Jiang Oncotarget.2016; 7(42): 69041. CrossRef
Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng, Pu-Yun OuYang, Fang-Yun Xie Oncotarget.2015; 6(41): 44019. CrossRef
Myung Wook Kim, Kyung Hee Lee, Jae Bok Chung, Jin Sil Sung, Hye Ran Lee, Jin Hyuk Chil, Hyun Cheol Chung, Woo Cheol Kim, Ki Chang Keum, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim
The prognosis of pancreati cancer is still poor in spite of advance in surgical treatment and parasurgical adjuvant management. Eighteen patients with histologically confirmed locally advanced adenocarcinoma of the pancreas were received radiation(5000cGy)+5-FU. Patients were treated with 5-FU 200 mg/m IV bolus, 1 hour before irradiation each day. In some patients, within 30 minutes after radiotherapy, hyperthemia was added to above protocol two times weekly. Median survival of total patients was 9.5months. Median survival with RT+ 5-FU was 12.7months from the date of treatment. Median survival with hyperthemia added group was 7.6months, but the survival dif- ference was not significant statistically. The side effects were acceptable. There were no episodes of any life threatening toxicities.